Vertaling van "scenario for informing the patient with regard " (Frans → Nederlands) :

The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but ( Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”.
The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but (Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”. Only 26% would choose to inform the patient outside the existing organs, and with a stronger preference on informing after the decision is taken.

Only 26% would choose to inform the patient outside the existing organs, and with a stronger preference on informing after the decision is taken. In the first scenario, there is no significant difference between the respondents with regard to the choice of the place where the information is given (inside or outside the existing decision-making organs) according their current/past membership (or not) of the INAMI – RIZIV organs.
In the first scenario, there is no significant difference between the respondents with regard to the choice of the place where the information is given (inside or outside the existing decision-making organs) according their current/past membership (or not) of the INAMI – RIZIV organs.

Scénarios d’implication des citoyens et des patients Différents scénarios pour informer ou consulter les citoyens ou les patients sont possibles.
Scenario's van burger- en patiëntenparticipatie Er zijn verschillende scenario’s mogelijk voor het informeren of consulteren van burgers of patiënten.

Les participants sont arrivés à définir un scénario pour l’information et la consultation des citoyens et des patients concernant des décisions spécifiques relatives à la détermination des priorités en matière de soins de santé et concernant le remboursement.
De deelnemers verkozen een scenario van informeren en consulteren voor beslissingen over de prioriteiten voor de gezondheidszorg en over de terugbetaling van producten en diensten.

Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

Les patients doivent être informés des signes et symptômes des réactions allergiques/d’hypersensibilité et doivent être étroitement surveillés au regard de ces symptômes (voir rubrique 4.8).
Patiënten dienen verwittigd te worden van de klachten en symptomen en dienen nauwlettend gecontroleerd te worden op symptomen van allergische/overgevoeligheidsreacties (zie rubriek 4.8).

The availability of the whole health information of a patient at any time by all care providers is a central question, linked to the one of the patient electronic medical record, and to the access to it. Two indicators under development reflect this issue: the % of general practices with access to the hospital data of their patient, and the % of
patient electronic medical record, and to the access to it. Two indicators under development reflect this issue: the % of general practices with access to the hospital data of their patient, and the % of

□ 4 séances d’information pour les médecins généralistes spécialistes de la région. □ 2 séances d’information pour les kinésithérapeutes et les psychologues. □ Organisation commune d’une journée d’étude interuniversitaire à Kortenberg (20/11/2004) □ présentation par affiche AACFS, Madion USA (8/10/04) : Formation of clinical network co-ordinating centres for patients with chronic fatigue syndrome □ 2 réunions de staff UZA sur le fonctionnement des centres de référence
□ 4 infosessies voor huisartsen /specialisten regio □ 2 infosessies voor kinesitherapeuten en psychologen □ mede-organisatie van een interuniversitaire studiedag in Kortenberg (20/11/2004) □ posterpresentatie AACFS, Madion USA (8/10/04) : Formation of clinical network coordinating centres for patients with chronic fatigue syndrome □ 2 stafvergaderingen UZA omtrent werking referentiecentra